Study identifier:D5180C00024
ClinicalTrials.gov identifier:NCT05398263
EudraCT identifier:2021-006691-17
CTIS identifier:N/A
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma (SUNRISE)
asthma
Phase 3
No
-
All
207
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
Amgen
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tezepelumab Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe. | Biological/Vaccine: Tezepelumab Tezepelumab subcutaneous injection Other Name: Tezepelumab |
Placebo Comparator: Placebo Placebo subcutaneous injection, in an accessorised pre-filled syringe. | Other: Placebo Placebo subcutaneous injection Other Name: Placebo |